Barney N P, Foster C S
Harvard Medical School, Boston, Massachusetts.
Cornea. 1994 May;13(3):232-6. doi: 10.1097/00003226-199405000-00007.
Corneal graft survival in 13 patients (14 eyes) receiving oral acyclovir after penetrating keratoplasty for herpes simplex keratitis was compared with that in nine patients (nine eyes) who underwent penetrating keratoplasty for herpes simplex keratitis without postoperative acyclovir. Mean age, duration of disease, and time of follow-up did not differ in the two groups. There were no recurrences of herpes simplex keratitis in any patient receiving acyclovir during a mean follow-up of 16.5 months compared with a 44% (four of nine) recurrence rate in patients without acyclovir during a mean follow-up of 20.6 months (p < 0.01). Graft failure occurred in 14% (2 of 14) of acyclovir treatment eyes compared with 56% (five of nine) without acyclovir. Long-term prophylactic oral acyclovir significantly decreased the recurrence of herpes simplex keratitis and reduced corneal graft failure in patients who had a history of recurrent herpes simplex keratitis and who had undergone penetrating keratoplasty.
对13例（14只眼）单纯疱疹性角膜炎穿透性角膜移植术后接受口服阿昔洛韦治疗的患者的角膜移植存活率，与9例（9只眼）单纯疱疹性角膜炎穿透性角膜移植术后未接受阿昔洛韦治疗的患者进行了比较。两组患者的平均年龄、病程和随访时间无差异。接受阿昔洛韦治疗的患者在平均16.5个月的随访期间均未发生单纯疱疹性角膜炎复发，而未接受阿昔洛韦治疗的患者在平均20.6个月的随访期间复发率为44%（9例中有4例）（p<0.01）。阿昔洛韦治疗组的移植失败率为14%（14只眼中有2只），未接受阿昔洛韦治疗组为56%（9只眼中有5只）。长期预防性口服阿昔洛韦可显著降低有单纯疱疹性角膜炎复发史且接受穿透性角膜移植术患者的单纯疱疹性角膜炎复发率，并减少角膜移植失败。
